Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia
- 507 Downloads
High-dose 5-fluorouracil (5-FU) containing chemotherapy occasionally causes hyperammonemia and can be lethal. However, the mechanism of 5FU-associated hyperammonemia has not been known. The aim of this study was to reveal the pharmacokinetics of 5-FU-associated hyperammonemia in a recurrent colorectal cancer patient with end-stage renal disease (ESRD).
We experienced a case of hyperammonemia during mFOLFOX6 plus bevacizumab therapy for recurrent colorectal cancer. He was a dialyzed patient due to diabetic nephropathy and was registered to prospective blood sampling for pharmacokinetics analysis during chemotherapy. Blood concentrations of 5-FU and its catabolites were determined by inductively coupled plasma-mass spectrometry.
The patient developed hyperammonemia encephalopathy 41 h after the initiation of continuous 5-FU infusion (on the third day). Before onset of hyperammonemia encephalopathy, serum alpha-fluoro-beta-alanine (FBAL, 59.2 µg/ml) and fluoro mono acetate (FMA, 905.8 ng/ml) were gradually increased. After hemodialysis for hyperammonemia, FBAL and FMA were collaterally decreased and his symptom was improved. Other intermediate catabolites of 5-FU, dihydrofluorouracil, and alpha-fluoro-beta-ureidopropionic acid were not changed.
We found increases of serum FBAL and FMA under the condition of hyperammonemia in the patient with ESRD during mFOLFOX6 plus bevacizumab therapy. This research supported the hypothesis that impairment of tricarboxylic acid (TCA) cycle by FMA would cause 5-FU-associated hyperammonemia.
Keywords5-Fluorouracil Hyperammonemia End-stage renal disease Pharmacokinetics
The authors express gratitude to all the staffs involved in this case.
Compliance with ethical standards
This research was partially supported by a grant from Kyoto University Research Development Program.
Conflict of interest
YN, TF, TH, SM, TM, SN, AY, and KM have no conflicts of interest to disclose. MY receives research grants from Astellas, Chugai, Daiichi Sankyo, Fujiyakuhin, Kyowa Hakko Kirin, Mitsubishi Tanabe Pharma Corporation, MSD, Nippon Boehringer Ingelheim, and Torii and is on advisory boards of Astellas. MM receives research funding from Chugai, Mitsui Knowledge Industry, Taiho, Nissha Printing, Olympus and Theravalues and is on advisory boards of Kewpie and Eisai.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.
Informed consent was obtained from the patient included in the study.
- 6.Iida T, Wagatsuma K, Tani M et al (2015) Four cases of 5-fluorouracil-related hyperammonemia in patients with large intestinal cancer and multiple liver metastases, including a case of hyperammonemia treated using hemodialysis. Nihon Shokakibyo Gakkai Zasshi 112:287–296. doi: 10.11405/nisshoshi.112.287 PubMedGoogle Scholar
- 8.Gamelin E, Delva R, Jacob J et al (2008) Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: Results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 26:2099–2105. doi: 10.1200/JCO.2007.13.3934 CrossRefPubMedGoogle Scholar
- 15.Bocci G, Danesi R, Allegrini G et al (2002) Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report. Eur J Clin Pharmacol 58:593–595. doi: 10.1007/s00228-002-0534-6 CrossRefPubMedGoogle Scholar